Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates-Reference-Cited by-同舟云学术

Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates

Published:2019-10-02 Issue:512 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Goedeke Leigh¹^ORCID,Peng Liang¹,Montalvo-Romeral Valle¹^ORCID,Butrico Gina M.¹,Dufour Sylvie¹,Zhang Xian-Man¹,Perry Rachel J.¹²^ORCID,Cline Gary W.¹^ORCID,Kievit Paul³^ORCID,Chng Keefe⁴^ORCID,Petersen Kitt Falk¹,Shulman Gerald I.¹²^ORCID

Affiliation:

1. Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, USA.

2. Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT 06510, USA.

3. Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.

4. Crown Bioscience Louisiana Inc., New Iberia, LA 70560, USA.

Abstract

Liver-targeted mitochondrial uncoupling improves dyslipidemia and reduces hepatic triglyceride content in obese nonhuman primates.

Funder

National Institutes of Health

National Cancer Institute

National Institute of Diabetes and Digestive and Kidney Diseases

Gilead Sciences